Axcellerate Pharma to open CRO/CMO in New Jersey
CRO Axcellerate Pharma is establishing a CMO/CRO and API manufacturing facility in New Jersey that will focus on small molecule and biologics PR&D, innovative technology platforms, filling vial and bag operations, peptide synthesis, oligonucleotide production and related areas.
Axcellerate Pharma is a joint venture set up by CRO TCG Lifesciences USA, with Dilip Mehta, founder and CEO of Panorama Consulting and Engineering, a developer of lab scale to GMP manufacturing facilities, and Alfagen Pharma, an affiliate of biotech AlfaGene Bioscience. The facility houses technology, equipment and infrastructure.
"We will initially target specialized CMC and CMO activities that are time sensitive and high value in nature, that are desirable to be located geographically close to our clients,” said Swapan Bhattacharya, managing director of TCG Lifesciences. Axcellerate plans to leverage its scientific talent pool, end-to-end capabilities and the PR&D/intermediate production facilities of TCG Lifesciences in India to support its operations. The alliance expands TCG Lifesciences’ geographic footprint and enable the company to serve clients in the U.S. with a local presence.
“AlfaGene Bioscience has developed proprietary assay platforms in a range of therapeutic indications and has a scientific team with extensive experience in biologics and biomedical research,” said Mayur Doshi, president and CEO, AlfaGene Bioscience.